Scienture expands REZENOPY™ distribution to opioid treatment clinics via partner
Scienture says an agreement with a distribution partner creates a dedicated channel for REZENOPY™ across about 2,000 U.S. OTP (Opioid Treatment Program) clinics and other addiction treatment networks. The company cites IQVIA data for the U.S. naloxone market (MAT July 2026).